CELENTYX LTD ENTERS INTO AGREEMENT WITH MEIJI SEIKA KAISHA, LTD TO DISCOVER NEW DEVELOPMENT PATHS FOR MEIJI DRUG CANDIDATES USING CELENTYX’S NOVEL CLINICAL INDICATION PROFILING™

BIRMINGHAM, UK August 24, 2009 – Celentyx Ltd announced today that it has entered into a drug reprofiling agreement with Meiji Seika Kaisha, Ltd to seek alternative development paths for Meiji drug candidates using an application of the Immuno-Profiling platform™ called Novel Clinical Indication Profiling™ (NCIP™). These drug candidates were previously discontinued or de-prioritized for reasons other than safety.

Celentyx’s proprietary NCIP™ identifies new uses for ‘safe’ drugs to treat human immune system diseases e.g. inflammation, haematological cancers (leukaemias and lymphomas), allergy, autoimmune disease and graft rejection. Celentyx research is at the forefront of the discovery and the elucidation of the role of novel targets in human immune system cells, many of these targets having formally been associated solely with the CNS. This expertise offers pharmaceutical partners a novel approach to bolster their pipelines with high-quality drug candidates that originated from their own R&D efforts.

Professor Nicholas Barnes, CEO of Celentyx Ltd, said, "We are particularly pleased to add Meiji as a partner since they have a number of candidate drugs impacting a target that we have identified on key cell subsets within the human immune system. Celentyx’s NCIP™ provides an efficient evaluation of a drug’s ability to signal responses in human immune cells with exceptionally high resolution to determine the therapeutic potential of small molecules and biologicals. Our goal is to provide partners with substantial value and revive development paths for drugs that retain potential for immune system disorders."

- ENDS -

Further information and high resolution images:
Dr Catherine Brady, Celentyx Ltd
Tel: +44 (0)121 414 8199 / Mobile: +44 (0)7725 963391
Email: catherine.brady@celentyx.com

www.celentyx.com

NOTES TO EDITORS

About Celentyx Ltd

Celentyx Ltd is a human immune system focused R&D and service company. Celentyx’s unique Immuno-Profiling™ platform allows identification of novel targets with therapeutic potential and rapid analysis of drug action on human immune cells. Drawing on the World-leading expertise of Celentyx personnel, which along with our close association with the MRC Centre for Immune Regulation, enables the human immune system to be investigated at the highest levels of resolution.

Celentyx's Immuno-Profiling™ services also enable partners to elucidate the mechanism of action of an immunomodulatory drug – at both the cellular and molecular level, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system prior to first administration to man.

About Meiji Seika Kaisha Ltd.

Meiji Seika Kaisha Ltd. is located in Tokyo, Japan and is operating its business in the fields of confectionaries and pharmaceuticals. In the pharmaceutical division, Meiji Seika is dedicated to the discovery, development and commercialization of a wide variety of pharmaceutical products throughout Japan and some countries outside of Japan, as well. The main areas of its interest are infectious disease and central nervous system disorders. For more information on Meiji Seika, please visit the company’s website at www.meiji.co.jp.